Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Perico
F Pusineri
G Remuzzi

Showing results (61-70 of 551) with videos related to

Pageof 56
Sort By:
Transplantation Proceedings|December 26, 2001
Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling?F Gaspari, R Caruso, D Cattaneo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 12, 1999
ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathyA Remuzzi, A Fassi, T Bertani, et al.
Experimental Nephrology|May 1, 1993
Intrathymic transplantation of donor cells allows a stabilized, incompatible renal transplant to survive indefinitely after cyclosporine withdrawalN Perico, M Rossini, O Imberti, et al.
The American Journal of Physiology|July 1, 1991
Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in ratsN Perico, A Remuzzi, J Dadan, et al.
Experimental Nephrology|July 1, 1994
Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damageN Perico, C S Amuchastegui, B Malanchini, et al.
Journal of the American Society of Nephrology : JASN|April 1, 1997
Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administrationF Gaspari, M F Anedda, O Signorini, et al.
Clinical Nephrology|September 1, 1982
Prostacyclin and renal diseasesN Perico, A Schieppati, G Mecca, et al.
Journal of the American Society of Nephrology : JASN|May 1, 1996
A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicityA Perna, E Gotti, E de Bernardis, et al.
The International Journal of Artificial Organs|March 1, 1980
Platelets from uraemic patients react normally to prostacyclinF Pusineri, E Gotti, G Remuzzi, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1990
17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanismG Viganò, C Zoja, D Corna, et al.
Pageof 56

Showing results (61-70 of 551) with videos related to

Sort By:
Pageof 56
Transplantation Proceedings|December 26, 2001
Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling?F Gaspari, R Caruso, D Cattaneo, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 12, 1999
ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathyA Remuzzi, A Fassi, T Bertani, et al.
Experimental Nephrology|May 1, 1993
Intrathymic transplantation of donor cells allows a stabilized, incompatible renal transplant to survive indefinitely after cyclosporine withdrawalN Perico, M Rossini, O Imberti, et al.
The American Journal of Physiology|July 1, 1991
Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in ratsN Perico, A Remuzzi, J Dadan, et al.
Experimental Nephrology|July 1, 1994
Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damageN Perico, C S Amuchastegui, B Malanchini, et al.
Journal of the American Society of Nephrology : JASN|April 1, 1997
Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administrationF Gaspari, M F Anedda, O Signorini, et al.
Clinical Nephrology|September 1, 1982
Prostacyclin and renal diseasesN Perico, A Schieppati, G Mecca, et al.
Journal of the American Society of Nephrology : JASN|May 1, 1996
A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicityA Perna, E Gotti, E de Bernardis, et al.
The International Journal of Artificial Organs|March 1, 1980
Platelets from uraemic patients react normally to prostacyclinF Pusineri, E Gotti, G Remuzzi, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1990
17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanismG Viganò, C Zoja, D Corna, et al.
Pageof 56